GH vs QGEN: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
GH is the larger of the two ($21.74B market cap): the incumbent the market prices for continued execution (-367.58x forward earnings, beta 1.59). QGEN is the smaller challenger ($8.54B), priced similarly on forward earnings (15.78x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
GH vs QGEN: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | GH | QGEN | What it tells you |
|---|---|---|---|
| Market cap | $21.74B | $8.54B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -367.58 | 15.78 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.59 | 0.64 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 89% of range | 35% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how GH and QGEN affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GH and QGEN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GH and QGEN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Guardant Health (GH) do?
Guardant Health is a precision-oncology company that reads cancer signals from blood and tissue samples. Its business runs across three lines. Oncology, the largest, sells tests like Guardant360 (comprehensive genomic profiling that helps match patients to targeted therapies) and Guardant Reveal (a blood test for minimal residual disease, meaning traces of cancer left after treatment). Biopharma and Data sells testing, companion-diagnostic development, and real-world data to drugmakers. Screening is the newest and most-watched line: Shield is the first blood test to win full FDA approval as a primary screening option for colorectal cancer in average-risk adults 45 and older. In Q1 2026 the company reported ~$302 million in revenue, with oncology up 36% to ~$205 million on ~86,000 tests, biopharma and data at ~$53 million, and screening at ~$41.6 million on ~44,000 Shield tests (versus ~$5.7 million a year earlier).
What does QIAGEN (QGEN) do?
QIAGEN makes the consumables and instruments labs use to collect, stabilize, purify, and analyze DNA and RNA, then extends into molecular diagnostics through platforms like QIAstat-Dx (syndromic infectious-disease testing), QuantiFERON (latent tuberculosis detection), and QIAcuity digital PCR. It serves more than 500,000 customers across molecular diagnostics, applied testing, academic research, and pharma, with a portfolio of 500-plus proprietary consumables and automated workflows. The December 2025 acquisition of Parse Biosciences pushed its Sample technologies franchise into single-cell analysis, one of five strategic growth pillars the company is steering toward its 2028 goals.
GH vs QGEN: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- GH drivers: Shield colorectal screening ramp; Core oncology growth and leverage.
- QGEN drivers: QIAstat-Dx syndromic testing; Sample technologies and single-cell.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Guardant is unprofitable and cash-consumptive, so it depends on the Shield launch converting into durable, reimbursed volume rather than one-off wins. For QGEN, quantiFERON tuberculosis sales have been a persistent drag and are exposed to competition and testing-volume swings.
GH or QGEN: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GH if you believe its drivers more; QGEN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GH and QGEN guides.
GH vs QGEN: the full fundamentals
GH. Figures are approximate and tied to the asOf date; verify live numbers before acting. GH trades on a high price-to-sales multiple typical of a fast-growing, pre-profit diagnostics company, so the valuation is driven by expected future growth rather than current earnings. The share price is volatile and moved sharply in mid-2026 on reimbursement news (including a July 2026 UnitedHealth coverage decision for Shield), which is why the timeline to 2027 cash-flow breakeven and the pace of Shield adoption matter more than any single quarter.
QGEN. Q1 2026 reported sales rose about 2 percent to roughly $492 million while constant-currency sales fell about 1 percent, and management guided full-year sales to about $2.1 billion and adjusted EPS to about $2.43, both below prior consensus. At a roughly $8.3 billion market cap the stock carries a mid-teens forward P/E, valuing it as a steady compounder rather than a high-growth name. The valuation reflects durable consumable revenue and margin discipline against low-single-digit organic growth.
Headline figures (approximate, July 2026): GH shows revenue (q1 2026 quarterly) ~$302 million, up 48% year over year, 2026 revenue guidance (full year) ~$1.30 to $1.32 billion (~32 to 34% growth), adjusted ebitda (q1 2026) ~-$59 million loss (still unprofitable), cash and equivalents ~$1.2 billion at quarter end; QGEN shows revenue (q1 2026) ~$492M, revenue (fy2026 guidance) ~$2.1B, adjusted eps (fy2026 guidance) ~$2.43, market cap ~$8.3B.
The bottom line: GH vs QGEN
GH and QGEN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GH and QGEN exposure against your real portfolio. It is not an investment adviser.
Wondering how GH or QGEN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Guardant Health with AI
Connect the broker you already use and ask Walnut's AI how GH fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between GH and QGEN?
+
Guardant Health is a precision-oncology company that reads cancer signals from blood and tissue samples. QIAGEN makes the consumables and instruments labs use to collect, stabilize, purify, and analyze DNA and RNA, then extends into molecular diagnostics through platforms like QIAstat-Dx (syndromic infectious-disease testing), QuantiFERON (latent tuberculosis detection), and QIAcuity digital PCR. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is GH or QGEN the better stock?
+
Neither is universally better. GH is the larger incumbent; QGEN is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, GH or QGEN?
+
On forward P/E (as of August 2026), GH trades at -367.58x and QGEN at 15.78x, so GH is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both GH and QGEN?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of GH vs QGEN?
+
GH: Guardant is unprofitable and cash-consumptive, so it depends on the Shield launch converting into durable, reimbursed volume rather than one-off wins. Reimbursement is the central swing factor: coverage decisions, guideline inclusion, and per-test pricing (the $1,495 Medicare rate, private payer terms) can move sharply and are outside the company's control. Competition is intense from Exact Sciences (Cologuard in colorectal screening), Natera (minimal residual disease), and Roche's Foundation Medicine (genomic profiling), which pressures pricing and share. Shield's clinical sensitivity, roughly 84% overall but lower for early-stage and precancerous lesions, invites scrutiny versus colonoscopy. The stock also trades at a high price-to-sales multiple, so any slip in growth or the breakeven timeline can trigger large swings. QGEN: QuantiFERON tuberculosis sales have been a persistent drag and are exposed to competition and testing-volume swings. A large share of revenue tracks academic, pharma, and life-sciences research budgets, which softened in the U.S. and remain sensitive to funding cycles. Roughly half of sales are outside the U.S., so currency moves materially affect reported results (reported growth outpaced constant-currency growth in Q1 2026). QIAGEN competes against much larger, better-capitalized rivals, and guidance cuts have shown the top line is vulnerable to demand shocks. Integration of acquisitions like Parse Biosciences carries execution risk.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell GH or QGEN; figures are approximate and dated (as of August 2026). Verify current data before investing.